The company's laboratory-developed test (LDT) for neurofilament light chain (NfL) also gained New York State approval as part of the permitting process.

The program offers lower-cost, refurbished testing instruments as well as customer education, inventory management, and enhanced service agreements.

Financial and other terms of the deal were not disclosed.

The all-virtual program is currently looking for a second cohort of novel diagnostics technologies, with a Sept. 30 deadline for new applications.

According to a company executive, the transactions will provide QuidelOrtho with greater financial flexibility while funding its continued growth.